Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$5.17 USD
-0.20 (-3.72%)
Updated Apr 24, 2024 03:15 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Aprea Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 22 | 29 | 53 | 89 | 130 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 4 | 3 | 3 |
Total Current Assets | 23 | 30 | 57 | 92 | 133 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 23 | 30 | 57 | 93 | 134 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 5 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 5 | 11 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 3 | 7 | 15 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 5 | 7 | 15 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 336 | 330 | 241 | 231 | 226 |
Retained Earnings | -308 | -294 | -181 | -144 | -91 |
Other Equity | -11 | -11 | -10 | -10 | -12 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17 | 26 | 50 | 77 | 124 |
Total Liabilities & Shareholder's Equity | 23 | 30 | 57 | 93 | 134 |
Total Common Equity | 17 | 26 | 50 | 77 | 124 |
Shares Outstanding | 3.70 | 2.60 | 1.00 | 1.00 | 1.00 |
Book Value Per Share | 4.58 | 9.86 | 49.51 | 77.40 | 124.24 |
Fiscal Year End for Aprea Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 22 | 25 | 28 | 31 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 0 | 1 | 1 |
Total Current Assets | NA | 23 | 26 | 29 | 32 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 23 | 26 | 29 | 32 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 3 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 0 | 0 | 0 |
Total Current Liabilities | NA | 4 | 4 | 4 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 6 | 5 | 5 | 6 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 336 | 336 | 335 | 335 |
Retained Earnings | NA | -308 | -305 | -301 | -298 |
Other Equity | NA | -11 | -11 | -11 | -11 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 17 | 20 | 23 | 26 |
Total Liabilities & Shareholder's Equity | NA | 23 | 26 | 29 | 32 |
Total Common Equity | 0 | 17 | 20 | 23 | 26 |
Shares Outstanding | 5.40 | 3.70 | 3.70 | 3.70 | 3.70 |
Book Value Per Share | 0.00 | 4.58 | 5.48 | 6.33 | 7.16 |